Skip to main content

Table 9 Antiangiogenic therapy in combination with other targeting therapies

From: Antiangiogenic therapy for breast cancer

  Combination
   Targeting angiogenesis Targeting HER1 or 2
Reference Chemotherapy Monoclonal antibody Tyrosine kinase inhibitor mTOR inhibitor Monoclonal antibody Tyrosine kinase inhibitor
Hurvitz et al. [89]       
Dickler et al. [90]   Bevacizumab     Erlotinib
Dickler et al. [91]   Bevacizumab     Lapatinib
Blay et al. [92]    Sunitinib   Trastuzumab  
Dirix et al. [93] Docetaxel   Sunitinib   Trastuzumab  
Slamon et al. [94]    Pazopanib    Lapatinib
O'Regan et al. [95] Paclitaxel    Everolimus Trastuzumab  
Yardley et al. [96]     Ridaforolimus Trastuzumab  
Mayer et al. [97]     Everolimus   Erlotinib
  1. HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin.